Richard Haupt, MD, MPH, explains how Pfizer is addressing the need for a C. difficile vaccine.
Richard Haupt, MD, MPH, vice president of Medical Development at Pfizer Vaccines, explains how Pfizer is addressing the need for a C. difficile vaccine.
Interview Transcript (modified slightly for readability):
“Pfizer is addressing the need for a C. difficile vaccine by investing in its development. For a number of years now, Pfizer has been working on vaccines that are really targeted for adult populations. We’re recognizing the importance of preventing disease in adults, helping adults who are living longer have a healthier and better quality of life as they live into older age groups and C. difficile is a perfect example of that. We’re investing in developing a vaccine that’s targeted at neutralizing the toxins, which are the mediators of C. difficile infection. We’re currently in a large phase 3 clinical and point efficacy trial, and, hopefully, that trial will demonstrate that the vaccine is both safe as well as efficacious.”